All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Pericarditis in chronic graft-versus-host disease
Pericardial effusion (PE) can be associated with chronic graft-versus-host disease (cGvHD) but the pathophysiology of the disease has not yet been extensively studied. To date, there is a lack of data on the risk and incidence of the condition. Ewa Karakulska-Prystupiuk from Medical University of Warsaw, Warsaw, Poland, and colleagues aimed to evaluate the incidence and risk factors of exudative pericarditis in patients with cGvHD. The results of the study were published in Transplantation Proceedings.
N = 105 patients who underwent allogenic hematopoietic stem cell transplantation (allo-HSCT) between 2010 and 2016 were included and analyzed retrospectively. Of them, 50 patients had cGvHD. Electrocardiography, echocardiography, N-terminal prohormone of brain natriuretic peptide (NT-proBNP) parameters were used.
Key findings:
- Incidence of pericarditis: 6 patients
- Endocrine disorders were observed in four patients
- Compensated hypothyroidism: 2 patients
- Hyperprolactinemia: 1 patient
- Iatrogenic ovarian insufficiency: 3 patients
- Iron overload was found in all patients
- Elevated NT-proBNP and signs of NYHA heart insufficiency grade II or III was found in all patients
- Only minor fluctuations were found in electrocardiogram
- One patient’s symptoms improved after glucocorticosteroid monotherapy, whereas other patients had to receive additional therapies such as tacrolimus plus sirolimus, rituximab, and extracorporeal photopheresis
Taken together, the authors stated that pericarditis may be observed up to 5% of allo-HSCT recipients, mainly in patients with moderate and severe chronic GvHD. Furthermore, GvHD related pericarditis can be treated with escalated dose of immunosuppressants resulting in favorable outcomes. The authors added that “early diagnosis may be achieved by systematic NT-proBNP testing and periodic echocardiogram evaluation. Further studies are needed to better understand the role of cytotoxic lymphocytes in the pathophysiology and diagnosis of PE.”
References